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Résumé en
anglais
Foscarnet is currently licensed for the treatment of human cytomegalovirus
(HCMV) infection. Mutations proven to confer resistance to foscarnet have mostly
been mapped to regions II, III and VI of the HCMV UL54-encoded DNA polymerase.
We previously showed that sequential foscarnet-resistant HCMV isolates recovered
from a patient with lymphoma had change N495K in region delta-C of the DNA
polymerase. To evaluate the impact of change N495K on HCMV sensitivity to
foscarnet, a recombinant HCMV strain carrying the mutation was produced by
homologous recombination. The recombinant virus showed a 3.4-fold increase in
foscarnet resistance, and remained sensitive to ganciclovir and cidofovir. In
addition, the recombinant strain showed a reduction of infectious virus yield
compared with its parent strain. Change N495K should be added to the list of
mutations conferring resistance to foscarnet and be taken into account in the






























Publié sur Okina (http://okina.univ-angers.fr)
